NYSEAMERICAN:RNN - Rexahn Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.57 +0.03 (+1.95 %)
(As of 06/25/2018 06:00 AM ET)
Previous Close$1.57
Today's Range$1.54 - $1.58
52-Week Range$1.42 - $3.19
Volume116,825 shs
Average Volume356,454 shs
Market Capitalization$52.33 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.35
Rexahn Pharmaceuticals logoRexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer. The company's clinical stage drug candidates include RX-3117, which is in Phase II a clinical trial for the treatment of patients with relapsed or refractory pancreatic cancer and advanced bladder cancer; and Supinoxin that is in Phase II a clinical study to treat patients with metastatic triple negative breast cancer. Rexahn Pharmaceuticals, Inc. is based in Rockville, Maryland.

Receive RNN News and Ratings via Email

Sign-up to receive the latest news and ratings for RNN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:RNN
CUSIPN/A
Phone+1-240-2685300

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-26.84%
Return on Assets-15.81%

Miscellaneous

EmployeesN/A
Outstanding Shares31,740,000

The Truth About Cryptocurrencies

Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) Frequently Asked Questions

What is Rexahn Pharmaceuticals' stock symbol?

Rexahn Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "RNN."

How were Rexahn Pharmaceuticals' earnings last quarter?

Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) posted its quarterly earnings results on Monday, May, 7th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.04. View Rexahn Pharmaceuticals' Earnings History.

What price target have analysts set for RNN?

3 brokerages have issued 12-month price targets for Rexahn Pharmaceuticals' stock. Their forecasts range from $13.00 to $20.00. On average, they anticipate Rexahn Pharmaceuticals' stock price to reach $16.50 in the next twelve months. View Analyst Ratings for Rexahn Pharmaceuticals.

Are investors shorting Rexahn Pharmaceuticals?

Rexahn Pharmaceuticals saw a decline in short interest during the month of May. As of May 31st, there was short interest totalling 2,407,915 shares, a decline of 5.3% from the May 15th total of 2,543,082 shares. Based on an average daily trading volume, of 338,082 shares, the days-to-cover ratio is currently 7.1 days. Currently, 7.8% of the shares of the company are sold short. View Rexahn Pharmaceuticals' Current Options Chain.

Who are some of Rexahn Pharmaceuticals' key competitors?

Who are Rexahn Pharmaceuticals' key executives?

Rexahn Pharmaceuticals' management team includes the folowing people:
  • Dr. Peter D. Suzdak, Chief Exec. Officer and Director (Age 59)
  • Dr. Ely Benaim M.D., Chief Medical Officer (Age 57)
  • Dr. Lisa Elizabeth Nolan Ph.D., Chief Bus. Officer (Age 56)
  • Mr. Douglas J. Swirsky, Pres & CFO (Age 49)
  • Dr. Reza Mazhari Ph.D., VP of Translational Medicine

Has Rexahn Pharmaceuticals been receiving favorable news coverage?

News coverage about RNN stock has trended somewhat positive on Monday, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Rexahn Pharmaceuticals earned a news sentiment score of 0.22 on Accern's scale. They also gave news articles about the company an impact score of 47.51 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are Rexahn Pharmaceuticals' major shareholders?

Rexahn Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Northern Trust Corp (0.24%). View Institutional Ownership Trends for Rexahn Pharmaceuticals.

Which institutional investors are buying Rexahn Pharmaceuticals stock?

RNN stock was purchased by a variety of institutional investors in the last quarter, including Northern Trust Corp. View Insider Buying and Selling for Rexahn Pharmaceuticals.

How do I buy shares of Rexahn Pharmaceuticals?

Shares of RNN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Rexahn Pharmaceuticals' stock price today?

One share of RNN stock can currently be purchased for approximately $1.57.

How big of a company is Rexahn Pharmaceuticals?

Rexahn Pharmaceuticals has a market capitalization of $52.33 million.

How can I contact Rexahn Pharmaceuticals?

Rexahn Pharmaceuticals' mailing address is 15245 Shady Grove Rd Ste 455, ROCKVILLE, MD 20850-7203, United States. The company can be reached via phone at +1-240-2685300.


MarketBeat Community Rating for Rexahn Pharmaceuticals (RNN)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  215 (Vote Outperform)
Underperform Votes:  152 (Vote Underperform)
Total Votes:  367
MarketBeat's community ratings are surveys of what our community members think about Rexahn Pharmaceuticals and other stocks. Vote "Outperform" if you believe RNN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RNN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.